<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2802245004
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Arexvy
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Recombinant respiratory syncytial virus prefusion F protein adjuvanted with AS01E
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and suspension for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        925.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GlaxoSmithKline Biologicals " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GlaxoSmithKline Biologicals 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Arexvy is a vaccine that helps to protect adults aged 60&nbsp;years and older against a virus called &lsquo;respiratory syncytial virus&rsquo; (RSV).<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_79779029-1da1-4cb1-b7be-1a95c54db5ff \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Arexvy also helps to protect against RSV in adults 50 through 59 years of age at increased risk for RSV disease.<!--[if supportFields]><span lang=EN-GB
style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b0061c24-5985-4829-85d5-37c5f6ee893c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>RSV is a respiratory virus that spreads very easily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RSV can cause lower respiratory tract disease - infections of the lungs and other parts of the body that help you breathe.</p><p>RSV infection usually causes mild, cold-like signs in healthy adults. But it can also:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cause more serious respiratory illnesses and complications, such as infections of the lungs (pneumonia), in older adults and adults with underlying medical conditions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; make some illnesses worse, such as long-term respiratory or heart diseases.</p><p><strong>How Arexvy works</strong></p><p>Arexvy helps your body&rsquo;s natural defences make antibodies and special white blood cells. These protect you against RSV.</p><p>Arexvy does not contain the virus. This means it cannot cause an infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Arexvy </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to the active substances or any of the other ingredients of this vaccine (listed in section 6).</p><p>Do not use Arexvy if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist.</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_810a2fd6-acf2-402b-aa91-5fccdbb9d2ed \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Talk to your doctor, pharmacist or nurse before you receive Arexvy if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a severe allergic reaction after the injection of any other vaccine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a severe infection with a high temperature (fever). If this happens, the vaccination may be delayed until you feel better. A minor infection such as a cold should not be a problem but talk to your doctor first</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a bleeding problem or bruise easily</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have fainted with a previous injection - fainting can happen before or after any needle injection.</p><p>If any of the above apply to you, or you are not sure, talk to your doctor or pharmacist before you have Arexvy.</p><p>As with all vaccines, Arexvy may not fully protect all people who are vaccinated.</p><p><strong>Other medicines/vaccines and Arexvy</strong></p><p>Tell your doctor or pharmacist if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have recently received any other vaccine.</p><p>Arexvy may be given at the same time as a flu vaccine.</p><p>If Arexvy is given at the same time as another injectable vaccine, a different injection site will be used for each vaccine, which means a different arm for each injection.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before you are given this vaccine.</p><p>Arexvy is not recommended during pregnancy or breast-feeding.<!--[if supportFields]><span lang=EN-GB style='font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_a44455a8-09f7-4e42-b159-20fa2abb6970 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Driving and using machines</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_06aed802-bfc4-4ab1-ab1e-e9a72fec6d16 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Some of the effects mentioned below in section 4 &ldquo;Possible side effects&rdquo; (e.g. feeling tired) may temporarily affect the ability to drive or use machines. Do not drive or use machines or tools if you are feeling unwell.</p><p><strong>Arexvy contains sodium and potassium</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f610cd0b-9d65-48f0-8d60-38d7937b86ad \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-fareast-font-family:"Times New Roman";mso-hansi-theme-font:major-bidi;
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>This medicine contains less than 1&nbsp;mmol (39&nbsp;mg) potassium per dose, i.e. essentially &lsquo;potassium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Arexvy is given as a single dose injection of 0.5&nbsp;mL into a muscle. It is usually given into the upper arm.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p><!--[if supportFields]><span
lang=EN-GB style='font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
color:white;mso-color-alt:windowtext;text-transform:none'><span
style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>The following side effects may happen after receiving Arexvy:</p><p><strong>&nbsp;</strong></p><p><strong>Very common</strong> (these may occur with more than 1 in 10 doses of the vaccine):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling tired (fatigue)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain (myalgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness where the injection is given.</p><p>&nbsp;</p><p><strong>Common</strong> (these may occur with up to 1 in 10 doses of the vaccine):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling where the injection is given</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills</p><p>&nbsp;</p><p><strong>Uncommon</strong> (these may occur with up to 1 in 100 doses of vaccine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching at the injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; generally feeling unwell (malaise)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged lymph nodes, or swollen glands in the neck, armpit or groin (lymphadenopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions such as rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you get any of the side effects listed above. Most of these side effects are mild to moderate in intensity and do not last long.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not freeze.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Arexvy contains </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are:</p><p>After reconstitution, one dose (0.5&nbsp;mL) contains:</p><p>RSVPreF3<sup>1</sup> antigen<sup>2,3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 120&nbsp;micrograms</p><p><sup>1</sup> Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3</p><p><sup>2 </sup>RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology</p><p><sup>3</sup> adjuvanted with AS01<sub>E</sub> containing:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; plant extract Quillaja saponaria Molina, fraction 21 (QS-21)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&nbsp;micrograms</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3-O-desacyl-4&rsquo;-monophosphoryl lipid A (MPL) from Salmonella minnesota&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25&nbsp;micrograms</p><p>&nbsp;</p><p>The RSVPreF3 is a protein present in the Respiratory Syncytial Virus. This protein is not infectious.</p><p>The adjuvant is used to improve the body&rsquo;s response to the vaccine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>o&nbsp;&nbsp; <strong>Powder </strong>(RSVPreF3 antigen): Trehalose dihydrate, polysorbate 80 (E 433), potassium dihydrogen phosphate (E 340), dipotassium phosphate (E 340).</p><p>o&nbsp;&nbsp; <strong>Suspension</strong>: Dioleoyl phosphatidylcholine (E 322), cholesterol, sodium chloride, disodium phosphate anhydrous (E 339), potassium dihydrogen phosphate (E 340) and water for injections.</p><p>See Section 2 &ldquo;Arexvy contains sodium and potassium&rdquo;.</p><p><strong>What Arexvy looks like and contents of the pack</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Powder and suspension for suspension for injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The powder is white.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The suspension is an opalescent, colourless to pale brownish liquid.</p><p>&nbsp;</p><p>One pack of Arexvy consists of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Powder (antigen) for 1 dose in a vial</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Suspension (adjuvant) for 1 dose in a vial</p><p>&nbsp;</p><p>Arexvy is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p><p><strong>The following information is intended for healthcare professionals only:</strong></p><p>Arexvy is presented as a vial with a mustard green flip-off cap containing the powder (antigen) and a vial with a brown flip-off cap containing the suspension (adjuvant).</p><p><br /><img alt="" width="421" height="168" src="data:image/png;base64,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" /></p><p>&nbsp;</p><p>The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not reconstitute the vaccine.</p><p>&nbsp;</p><p><u>How to prepare Arexvy:</u></p><p>Arexvy must be reconstituted prior to administration.</p><p>&nbsp;</p><p>1. Withdraw the entire contents of the vial containing the suspension into the syringe.</p><p>2. Add the entire contents of the syringe into the vial containing the powder.</p><p>3. Gently swirl until the powder is completely dissolved.</p><p>&nbsp;</p><p>&nbsp;</p><p>The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.</p><p>&nbsp;</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.</p><p>&nbsp;</p><p>Chemical and physical in-use stability has been demonstrated for 4 hours at 2 &deg;C &ndash; 8 &deg;C or at room temperature up to 25 &deg;C.</p><p>From a microbiological point of view, the product should be used immediately.</p><p>If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 4 hours.</p><p>&nbsp;</p><p><u>Before administration:</u></p><p>1. Withdraw 0.5 mL of the reconstituted vaccine into the syringe.</p><p>2. Change the needle so that you are using a new needle.</p><p>&nbsp;</p><p>Administer the vaccine intramuscularly.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p><strong>&nbsp;</strong></p><p><strong>AREXVY</strong> is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy;2024 GSK group of companies or its licensor.</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Arexvy looks like and contents of the pack
•	Powder and suspension for suspension for injection.
•	The powder is white.
•	The suspension is an opalescent, colourless to pale brownish liquid.
	
	One pack of Arexvy consists of: 
•	Powder (antigen) for 1 dose in a vial
•	Suspension (adjuvant) for 1 dose in a vial
	
	Arexvy is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension.
	
	Not all pack sizes may be marketed.
	
The following information is intended for healthcare professionals only:
Arexvy is presented as a vial with a mustard green flip-off cap containing the powder (antigen) and a vial with a brown flip-off cap containing the suspension (adjuvant).




The powder and suspension should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not reconstitute the vaccine.

How to prepare Arexvy:
Arexvy must be reconstituted prior to administration.

1. Withdraw the entire contents of the vial containing the suspension into the syringe.
2. Add the entire contents of the syringe into the vial containing the powder.
3. Gently swirl until the powder is completely dissolved.


The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.

Chemical and physical in-use stability has been demonstrated for 4 hours at 2 °C – 8 °C or at room temperature up to 25 °C.
From a microbiological point of view, the product should be used immediately.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 4 hours.

Before administration:
1. Withdraw 0.5 mL of the reconstituted vaccine into the syringe.
2. Change the needle so that you are using a new needle.

Administer the vaccine intramuscularly.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
	
	AREXVY is a trademark owned by or licensed to the GSK group of companies.
	©2024 GSK group of companies or its licensor.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder </strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; KSA.</p><p>*Member of GSK group of companies</p><p><strong>&nbsp;</strong></p><p><strong>Manufactured by : </strong></p><p>GlaxoSmithKline Biologicals SA, Avenue Fleming, 20, 1300 Wavre, Belgium</p><p><strong>Release by:</strong></p><p>GlaxoSmithKline Biologicals SA* Rue de l&rsquo;Institut 89, 1330 Rixensart, Belgium</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;</strong><strong>Version Date:</strong> <strong>26 August 2024</strong></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;Version Number: </strong>EMAv05 (26-08-2024)</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                                                                     Version Date: 26 August 2024
	                                                 Version Number: EMAv05 (26-08-2024)

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أريكسفي هو لقاح يساعد على حماية البالغين الذين تبلغ أعمارهم 60 عامًا أو أكثر ضد فيروس يسمى &quot;الفيروس التنفسي المخلوي&quot; (RSV).</p><p dir="RTL">أريكسفي يساعد أيضًا على الحماية ضد فيروس التنفسي المخلوي لدى البالغين الذين تتراوح أعمارهم بين 50 إلى 59 عامًا والذين هم أكثر عرضة للإصابة بمرض فيروس التنفسي المخلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الفيروس التنفسي المخلوي هو فيروس تنفسي ينتشر بسهولة شديدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يتسبب الفيروس التنفسي المخلوي في مرض الجهاز التنفسي السفلي أو يُسبب عدوى في الرئتين والأجزاء الأخرى من الجسم التي تساعدك على التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عدوى الفيروس التنفسي المخلوي عادةً ما تسبب علامات خفيفة تشبه البرد لدى البالغين الاصحاء. ولكن يمكنه أيضًا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن يُسبب أمراض تنفسية أكثر خطورة ومضاعفاتها، مثل التهابات الرئتين (الالتهاب الرئوي)، عند كبار السن والبالغين الذين يعانون من حالات طبية غير ظاهرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم بعض الأمراض، مثل أمراض الجهاز التنفسي أو أمراض القلب على المدى الطويل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آلية عمل أريكسفي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يساعد أريكسفي الدفاعات الطبيعية لجسمك على تكوين أجسام مضادة وخلايا دم بيضاء خاصة. هذه تحميك من الفيروس التنفسي المخلوي.</p><p dir="RTL">لا يحتوي أريكسفي على الفيروس. هذا يعني أنه لا يمكن أن يسبب عدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم استخدام لقاح أريكسفي</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه المواد الفعالة أو أي من المكونات الأخرى لهذا اللقاح (المدرجة في القسم 6).</p><p dir="RTL">لا تستخدم أريكسفي إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا، تحدث إلى طبيبك المعالج أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك المعالج أو الصيدلي أو الممرضة قبل أن تتلقى أريكسفي إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني في الماضي من رد فعل تحسسي شديد بعد حقن أي لقاح آخر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من عدوى شديدة مع ارتفاع في درجة الحرارة (حمى). إذا حدث هذا، فقد يتأخر التطعيم حتى تشعر بالتحسن. لا ينبغي أن تكون العدوى البسيطة مثل الزكام مشكلة ولكن تحدث إلى طبيبك أولاً.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من سهولة الإصابة بنزيف أو كدمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرضت للإغماء من حقنة سابقة -يمكن أن يحدث الإغماء قبل حقن أي إبرة أو بعده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبق عليك أي مما سبق، أو لم تكن متأكدًا، تحدث إلى طبيبك المعالج أو الصيدلي قبل أن تحصل على أريكسفي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كما هو الحال مع جميع اللقاحات، قد لا يوفر أريكسفي الحماية الكاملة لجميع الأشخاص الذين يتم تطعيمهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعل بين الأدوية أو اللقاحات الأخرى مع أريكسفي</strong></p><p dir="RTL">أخبر طبيبك المعالج أو الصيدلي إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أو تناولت مؤخرًا أو يمكن أن تتناول أي أدوية أخرى. وهذا يشمل الأدوية التي يتم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقيت مؤخرًا أي لقاح آخر.</p><p dir="RTL">يمكن إعطاء أريكسفي في نفس الوقت مع لقاح الأنفلونزا.</p><p dir="RTL">إذا تم إعطاء أريكسفي في نفس الوقت مع لقاح آخر قابل للحقن، فسيتم استخدام موقع حقن مختلف لكل لقاح، مما يعني ذراعًا مختلفًا لكل حقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت حاملاً أو ترضعين طبيعيًا، أو تعتقدي أنكى قد تكونين حاملًا، أو إذا كنت تخططين لإنجاب طفل، فتحدثي مع الطبيب المعالج أو الصيدلي للحصول على المشورة قبل تلقي هذا اللقاح.</p><p dir="RTL">لا ينصح بتلقي أريكسفي أثناء الحمل أو الرضاعة الطبيعية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تؤثر بعض الآثار المذكورة أدناه في القسم 4 &quot;الآثار الجانبية المحتملة&quot; (مثل الشعور بالتعب) مؤقتًا على القدرة على القيادة أو استخدام الآلات. لا تقود السيارة أو تستخدم الآلات أو الأدوات إذا كنت تشعر بتوعك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي أريكسفي على الصوديوم والبوتاسيوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملي مول من الصوديوم (23 مجم) لكل جرعة، وهذا يعني بشكل أساسي &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 ملي مول (39 مجم) من البوتاسيوم لكل جرعة، أي بشكل أساسي &quot;خالي من البوتاسيوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم إعطاء لقاح أريكسفي كحقنة وحيدة بجرعة 0.5 مل في العضل. عادة ما يتم إعطاؤه في الجزء العلوي من الذراع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">يمكن أن تحدث الآثار الجانبية التالية بعد تلقي لقاح أريكسفي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا</strong> (يمكن أن تحدث مع أكثر من جرعة واحدة من كل 10 جرعات من اللقاح):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في موقع الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم عضلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم مفصلي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في مكان الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(يمكن أن تحدث مع ما يصل إلى جرعة واحدة من كل 10 جرعات من اللقاح):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في مكان الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (يمكن أن تحدث مع ما يصل إلى جرعة واحدة من كل 100 جرعة من اللقاح):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة في موقع الحقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور العام بالتوعك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الغدد الليمفاوية أو تورم الغدد الموجودة في الرقبة أو الإبط أو الفخذ (تضخم العقد اللمفية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية مثل الطفح الجلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك المعالج أو الصيدلي إذا كنت تعاني من أي من الآثار الجانبية المذكورة أعلاه. معظم هذه الآثار الجانبية خفيفة إلى معتدلة الشدة ولا تدوم طويلاً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تفاقمت أي من الآثار الجانبية، أو إذا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة، فيرجى إخبار طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; احفظ هذا الدواء بعيدًا عن أنظار الأطفال ومتناول أيديهم.</p><p dir="RTL">&bull; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على الملصق والعلبة بعد EXP انتهاء الصلاحية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&bull; يحفظ في الثلاجة (من 2 درجة مئوية إلى 8 درجة مئوية).</p><p dir="RTL">&bull; لا يُجمد.</p><p dir="RTL">&bull; يجب التخزين في العلبة الأصلية للحماية من الضوء.</p><p dir="RTL">&bull; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي لقاح أريكسفي</strong></p><p dir="RTL">المواد الفعالة هي:</p><p dir="RTL">بعد إعادة التركيب، تحتوي جرعة واحدة (0.5 مل) على:</p><p dir="RTL">RSVPreF3<sup>1</sup> antigen<sup>2,3</sup> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;120 ميكرو جرام</p><p dir="RTL">&nbsp;</p><p dir="RTL"><sup>1</sup>استقر البروتين السكري إف المؤتلف بالفيروس التنفسي المخلوي في التشكل قبل الاندماج = RSVPreF3</p><p dir="RTL"><sup>2</sup>يتم إنتاج RSVPreF3 في خلايا مبيض الهامستر الصيني (CHO) بواسطة تقنية الحمض النووي المؤتلف</p><p dir="RTL"><sup>3</sup>المساعدة مع AS01<sub>E</sub> التي تحتوي على:</p><p dir="RTL">مستخلص نباتي كويلاجا سابوناريا مولينا، جزء 21 (QS-21)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ميكرو جرام</p><p dir="RTL">3-أو-ديساسيل -4&#39;-أحادي الفوسفوريل ليبيد أ من السالمونيلا مينيسوتا&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 ميكرو جرام</p><p dir="RTL">&nbsp;</p><p dir="RTL">RSVPreF3 هو بروتين موجود في الفيروس التنفسي المخلوي. هذا البروتين غير معدي.</p><p dir="RTL">تُستخدم المادة المساعدة لتحسين استجابة الجسم للقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL"><strong>المسحوق</strong> (مستضد RSVPreF3): تريهالوز ثنائي هيدرات، بولي سوربات 80 (إي 433)، بوتاسيوم ثنائي هيدروجين الفوسفات (إي 340)، فوسفات ثنائي البوتاسيوم (إي 340)</p><p dir="RTL"><strong>المعلق:</strong> ديوليويل فوسفاتيديل كولين (إي 322)، الكوليسترول، كلوريد الصوديوم، فوسفات ثنائي الصوديوم، لا مائي (إي 339)، بوتاسيوم ثنائي هيدروجين الفوسفات (إي 340)، ماء للحقن</p><p dir="RTL">انظر القسم 2 &quot;يحتوي أريكسفي على الصوديوم والبوتاسيوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو لقاح أريكسفي وما هي محتويات العبوة</strong></p><p dir="RTL">&bull; مسحوق ومعلق للحصول على معلق للحقن.</p><p dir="RTL">&bull; المسحوق أبيض.</p><p dir="RTL">&bull; المعلق سائل براق، عديم اللون يميل إلى اللون البني الشاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي عبوة واحدة من أريكسفي على:</p><p dir="RTL">&bull; مسحوق (مستضد) لجرعة واحدة في فيال.</p><p dir="RTL">&bull; معلق (مساعد) لجرعة واحدة في فيال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر أريكسفي في عبوة تحتوي على فيال واحد من المسحوق بالإضافة إلى فيال واحد يحتوي على معلق، أو في عبوة تحتوي على 10 فيال من المسحوق بالإضافة إلى 10 فيال معلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المعلومات التالية مخصصة لمتخصصي الرعاية الصحية فقط:</strong></p><p dir="RTL">يتوفر أريكسفي في شكل فيال ذات غطاء قلاب بلون الخردل الأخضر يحتوي على مسحوق (مولد المضاد )، وفيال أخر ذات غطاء قلاب بلون بني يحتوي على معلق (مساعد مولد المضاد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إعادة تركيب المسحوق والمعلق قبل الإعطاء.</p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>مساعد مولد المضاد</strong></p><p dir="RTL">المعلق</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>جرعة واحدة (0.5 مل)</strong></p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL"><strong>مولد المضاد</strong></p><p dir="RTL">المسحوق</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب فحص المسحوق والمعلق بصريًا بحثًا عن أي جسيمات غريبة أو اختلاف في المظهر أو كلاهما. إذا لوحظ أي منهما، فلا يجب إعادة تركيب اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>كيفية تحضير اريكسفي</u></p><p dir="RTL">يجب إعادة تركيب اريكسفي قبل الإعطاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">1-&nbsp;&nbsp;&nbsp; اسحب كامل محتويات الفيال الذي يحتوي على المعلق إلى سرنجة.</p><p dir="RTL">2-&nbsp;&nbsp;&nbsp; أضف محتويات السرنجة بالكامل إلى الفيال الذي يحتوي على المسحوق.</p><p dir="RTL">3-&nbsp;&nbsp;&nbsp; حرك بلطف حتى يذوب المسحوق تمامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اللقاح المعاد تكوينه هو سائل براق، عديم اللون يميل إلى البني الشاحب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب فحص اللقاح المعاد تكوينه بصريًا بحثًا عن أي جسيمات غريبة أو اختلاف في المظهر أو كلاهما. إذا لوحظ أي منهما، فلا يجب إعطاء اللقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي أثناء الاستخدام لمدة 4 ساعات عند 2 درجة مئوية حتى 8 درجات مئوية أو في درجة حرارة الغرفة حتى 25 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة النظر الميكروبيولوجية، يجب استخدام المنتج على الفور.</p><p dir="RTL">إذا لم يتم استخدامه على الفور، فإن أوقات التخزين أثناء الاستخدام وظروفه قبل الاستخدام هي مسؤولية المستخدم ويجب ألا تزيد عن 4 ساعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قبل الإعطاء</u></p><p dir="RTL">1-&nbsp;&nbsp;&nbsp; اسحب 0.5 مل من اللقاح المعاد تكوينه في السرنجة.</p><p dir="RTL">2-&nbsp;&nbsp;&nbsp; قم بتغيير الإبرة بحيث تستخدم إبرة جديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطى اللقاح عن طريق الحقن العضلي.</p><p dir="RTL">يجب التخلص من أي منتج طبي أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اريكسفي </strong>هي علامة تجارية مملوكة لمجموعة شركات جلاكسوسميث كلاين أو مرخصة لها.</p><p dir="RTL">حقوق الطبع والنشر &copy; لعام 2024 لمجموعة شركات جلاكسوسميث كلاين أو الجهات المرخص لها.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التسويق</strong><strong>:</strong></p><p dir="RTL">جلاكسو المملكة العربية السعودية المحدودة، جدة *، المملكة العربية السعودية</p><p dir="RTL">العنوان: ص.ب 22617، جدة 21416-المملكة العربية السعودية.</p><p dir="RTL">* عضو في مجموعة شركات جلاكسو سميث كلاين</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">GlaxoSmithKline Biologicals SA, Avenue Fleming, 20, 1300 Wavre, Belgium</p><p dir="RTL"><strong>الشركة المٌصدرة:</strong></p><p dir="RTL">GlaxoSmithKline Biologicals SA*<strong> </strong>Rue de l&rsquo;Institut 89<strong> , </strong>1330 Rixensart<strong> </strong>Belgium</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تاريخ الإصدار:26 اغسطس 2024 </strong></p><p dir="RTL"><strong>رقم الإصدار:</strong> <strong>EMAv05 (</strong><strong>26-08-2024</strong><strong>)</strong><strong> </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666-12-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: -56-904-9882966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: gcc.medinfo@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>- </strong><strong>جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666-12-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: -9882-904-56&nbsp; 966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: <u>s</u>audi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: <u>https://gskpro.com/en-sa/ </u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;ص.ب. 55850، جدة 21544، المملكة العربية السعودية.&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>إن هذا الدواء</strong></p><p dir="RTL">- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر.</p><p dir="RTL">- اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليها، وتعليمات الصيدلي الذي صرفها لك.</p><p dir="RTL">- الطبيب والصيدلي هما الخبيران في الدواء، وفي نفعه وضرره.</p><p dir="RTL">- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.</p><p dir="RTL">- لا تكرر صرف الدواء بدون استشارة الطبيب المختص.</p><p dir="RTL">- لا تترك الأدوية في متناول الاطفال.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مجلس وزراء الصحة العرب</strong></p><p dir="RTL"><strong>اتحاد الصيادلة العرب</strong></p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تاريخ الإصدار:26 اغسطس 2024 
رقم الإصدار: EMAv05 (26-08-2024) 
 

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arexvy powder and suspension for suspension for injection
Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, one dose (0.5 mL) contains:
RSVPreF31 antigen2,3							120 micrograms

1 Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation = RSVPreF3
2 RSVPreF3 produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology 
3 adjuvanted with AS01E containing:
	plant extract Quillaja saponaria Molina, fraction 21 (QS-21)	25 micrograms
	3-O-desacyl-4’-monophosphoryl lipid A (MPL) from Salmonella minnesota												25 micrograms

For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and suspension for suspension for injection.

The powder is white.
The suspension is an opalescent, colourless to pale brownish liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in</p><p>&middot;&nbsp;&nbsp; adults 60&nbsp;years of age and older.</p><p>&middot;&nbsp;&nbsp; adults 50 through 59 years of age who are at increased risk for RSV disease.</p><p>&nbsp;</p><p>The use of this vaccine should be in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Arexvy is administered as a single dose of 0.5&nbsp;mL.</p><p>The need for revaccination with a subsequent dose has not been established (see section 5.1).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p>The safety and efficacy of Arexvy in children have not been established.</p><p>No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>For intramuscular injection only, preferably in the deltoid muscle.</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Prior to immunisation</u></p><p>Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.</p><p>&nbsp;</p><p>Vaccination should be postponed in individuals suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.</p><p>&nbsp;</p><p>As with any vaccine, a protective immune response may not be elicited in all vaccinees.</p><p>&nbsp;</p><p>Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress‐related reactions may occur in association with the vaccination process itself. It is important that precautions are in place to avoid injury from fainting.</p><p>&nbsp;</p><p><u>Precautions for use</u></p><p>Do not administer the vaccine intravascularly or intradermally. No data are available on subcutaneous administration of Arexvy.</p><p>&nbsp;</p><p>As with other intramuscular injections, Arexvy should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following intramuscular administration to these individuals.</p><p>&nbsp;</p><p><u>Systemic immunosuppressive medicinal products and immunodeficiency</u></p><p>Safety and immunogenicity data on Arexvy are not available for immunocompromised individuals. Patients receiving immunosuppressive treatment or patients with immunodeficiency may have a reduced immune response to Arexvy.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Excipients </u></p><p>This medicinal product contains potassium, less than 1&nbsp;mmol (39&nbsp;mg) per dose, i.e. essentially &lsquo;potassium-free&rsquo;.</p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Use with other vaccines</u></p><p>Arexvy may be administered concomitantly with inactivated seasonal influenza vaccines (standard dose, unadjuvanted, high dose unadjuvanted, or standard dose adjuvanted).</p><p>Upon concomitant administration of Arexvy with seasonal influenza vaccines, numerically lower RSV A and B neutralising titres and numerically lower influenza A and B haemagglutination inhibition titres were observed as compared to the separate administration. This was not observed consistently across studies. The clinical relevance of these findings is unknown.</p><p>&nbsp;</p><p>If Arexvy is to be given at the same time as another injectable vaccine, the vaccines should always be administered at different injection sites.</p><p>&nbsp;</p><p>Concomitant administration of Arexvy with other vaccines than those listed above has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data from the use of Arexvy in pregnant women. After administration of an investigational unadjuvanted RSVPreF3 vaccine to 3&nbsp;557 pregnant women in a single clinical study, an increase in preterm births was observed compared to placebo. Currently no conclusion on a causal relationship between administration of unadjuvanted RSVPreF3 and preterm birth can be drawn. Results from animal studies with Arexvy or with an investigational unadjuvanted RSVPreF3 vaccine do not indicate direct or indirect harmful effects with respect to developmental and reproductive toxicity (see section 5.3). Arexvy is not recommended during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There are no data on the excretion of Arexvy in human or animal milk. Arexvy is not recommended in breast-feeding/lactating women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the effects of Arexvy on human fertility. Animal studies with Arexvy or with an investigational unadjuvanted RSVPreF3 vaccine do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of Arexvy on the ability to drive and use machines have been performed.</p><p>&nbsp;</p><p>Arexvy has a minor influence on the ability to drive and use machines. Some of the effects mentioned under section 4.8 &ldquo;Undesirable effects&rdquo; (e.g. fatigue) may temporarily affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The safety profile presented in Table 1 is based on a pooled analysis of data generated in two placebo-controlled Phase III clinical studies (conducted in Europe, North America, Asia and Southern hemisphere) in adults &ge;&nbsp;60&nbsp;, and 50 through 59 years of age .</p><p>&nbsp;</p><p>In study participants 60&nbsp;years of age and older, (more than 12 000 adults received one dose of Arexvy and more than 12 000 received placebo, with a follow-up period of approximately 12 months), the most commonly reported adverse reactions were injection site pain (61%), fatigue (34%), myalgia (29%), headache (28%), and arthralgia (18%). These adverse reactions were usually mild or moderate in intensity and resolved within a few days after vaccination.</p><p>Most other adverse reactions were uncommon and similarly reported between the study groups.</p><p>In study participants 50 through 59 years of age (769 participants, including 386 participants with pre-defined, stable, chronic medical conditions leading to an increased risk for RSV disease), a higher incidence of injection site pain (76%), fatigue (40%), myalgia (36%), headache (32%), and arthralgia (23%) was observed, compared with those 60 years of age and older (381 participants) in the same study. However, the duration and severity of these events were comparable across age groups in the study.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed below by MedDRA system organ class and frequency.</p><p>&nbsp;</p><p>Very common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/10)</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/100 to &lt;&nbsp;1/10)</p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100)</p><p>Rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000)</p><p>Very rare&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt;&nbsp;1/10&nbsp;000)</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Table 1. Adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>System Organ Class</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_cf1fd4c3-34d6-4820-afa9-20c57f0b0d64 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE'><span style='mso-element:field-end'></span></span></b><![endif]--></p></td><td><p><strong>Frequency</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
  normal'><span lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:
  FR-BE'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_3336bb8c-8a22-4e31-a6a5-d62575f5b3a6 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE'><span style='mso-element:field-end'></span></span></b><![endif]--></p></td><td><p><strong>Adverse reactions</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_72d58d2e-6c70-4f03-a545-b69dd2c114c2 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE'><span style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr><tr><td><p>Blood and lymphatic system disorders<!--[if supportFields]><span lang=EN-GB
  style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;mso-bidi-font-weight:
  bold'><span style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_b1c1a8ae-3848-418c-adc1-8a7b1ad2a275 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>Uncommon<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_76dbcda5-9846-4c87-81e8-29ed38b4cb1f \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>lymphadenopathy<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_0ff144fd-bc93-4eb3-8101-60cdf04a44e9 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td><p>Immune system disorders<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE;mso-bidi-font-weight:bold'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_25e971fe-fdf9-45b9-aacc-de250d29746b \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>Uncommon<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_dc91cc10-53dd-4fe2-b78a-ad6a4dc54a34 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>hypersensitivity reactions (such as rash)<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_6e33b313-fd08-4063-8fe1-c954d8bf776d \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td><p>Nervous system disorders<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE;mso-bidi-font-weight:bold'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_dff75781-dd49-4aba-b82f-6a0c72ca3faf \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>Very common<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_84317a4f-7848-4720-926a-2fbe1db3a6d1 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>headache<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_7819b762-7820-406b-9b51-6e29a9458b11 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td><p>Gastrointestinal disorders<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE;mso-bidi-font-weight:bold'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_2c1f322a-f014-4cca-b03d-84ff9e35e1cf \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>Uncommon<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_e0fa7aa7-2e5a-476a-9ba8-7eddbe515d65 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>nausea, abdominal pain, vomiting<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_8d8977fe-46d7-417c-98b0-6e73639395b9 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td><p>Musculoskeletal and connective tissue disorders<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_62b8d546-5847-40ad-ae2b-8616faac3b30 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>Very common<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_9e3215a7-c6bb-4061-8f80-7fa2d8d502ac \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>myalgia, arthralgia<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE;mso-bidi-font-weight:bold'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_ae5904f8-1b70-4f94-82bb-63c7db1925c9 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td rowspan="4"><p>General disorders and administration site conditions<!--[if supportFields]><span lang=EN-GB style='mso-bidi-font-size:
  11.0pt;mso-fareast-language:FR-BE'><span style='mso-element:field-begin'></span>
  DOCVARIABLE vault_nd_36cf5b53-b678-4ce0-a51c-590095b8f0d1 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>Very common<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_97f5b0ac-0257-4d30-8f29-7fab460bdcd0 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>injection site pain, injection site erythema, fatigue<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span></span><span
  lang=FR style='mso-bidi-font-size:11.0pt;mso-ansi-language:FR;mso-fareast-language:
  FR-BE;mso-bidi-font-weight:bold'> DOCVARIABLE
  vault_nd_fb5eb728-6c19-4870-ad3b-ddde20542581 \* MERGEFORMAT </span><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE;
  mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td><p>Common<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_268391a2-1626-4444-8ed8-e18ce169cca0 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td><td><p>injection site swelling, fever, chills<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_28b4dfce-be9c-40c1-bac8-dd89e8e83e5d \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td rowspan="2"><p>Uncommon<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_009c6ecf-c914-4682-a07b-4f491acc5729 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p></td><td><p>injection site pruritus<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_0e04f9fc-14dc-4b27-b055-09593b68f845 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td><p>pain, malaise<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-begin'></span> DOCVARIABLE
  vault_nd_d9315241-ed15-4bc6-9e14-acff5b724010 \* MERGEFORMAT <span
  style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
  lang=EN-GB style='mso-bidi-font-size:11.0pt;mso-fareast-language:FR-BE'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>&nbsp;</p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Reporting Hotline : 19999​</p><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-G</strong><strong>SK</strong><strong> - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp; Email: saudi.safety@gsk.com<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported in the clinical studies.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Vaccines, other viral vaccines, ATC code: J07BX05.</p><p><u>Mechanism of action</u></p><p>By combining the RSV-specific antigen, F-protein in prefusion conformation, with an adjuvant system (AS01<sub>E</sub>), Arexvy is designed to enhance antigen-specific cellular immune response and neutralizing antibodies response in individuals with pre-existing immunity against RSV. The adjuvant AS01<sub>E</sub> facilitates the recruitment and activation of antigen presenting cells carrying vaccine-derived antigens in the draining lymph node, which in turn leads to the generation of RSVPreF3-specific CD4+ T cells.</p><p>&nbsp;</p><p><u>Efficacy </u></p><p>Efficacy against RSV-associated LRTD in adults 60&nbsp;years and older was evaluated in an ongoing, Phase III, randomised, placebo-controlled, observer-blind clinical study conducted in 17 countries from Northern and Southern Hemispheres. Participants are planned to be followed for up to 36&nbsp;months.</p><p>The primary population for efficacy analysis (referred to as the modified Exposed Set, defined as adults 60&nbsp;years of age and older who received 1 dose of Arexvy or placebo and who did not report an RSV-confirmed acute respiratory illness [ARI] prior to Day 15 after vaccination) included 24&nbsp;960 participants randomised equally to receive 1 dose of Arexvy (N = 12&nbsp;466) or placebo (N = 12&nbsp;494). At the time of the first confirmatory efficacy analysis, participants had been followed for the development of RSV-associated LRTD for a median of 6.7&nbsp;months.&nbsp;</p><p>The median age of participants was 69&nbsp;years (range: 59 to 102&nbsp;years), with approximately 74% over 65&nbsp;years of age, approximately 44% over 70&nbsp;years of age and approximately 8% over 80&nbsp;years of age. Approximately 52% were female. At baseline, 39.3% of participants had at least one comorbidity of interest; 19.7% of participants had an underlying cardiorespiratory condition (COPD, asthma, any chronic respiratory/pulmonary disease, or chronic heart failure) and 25.8% of participants had endocrinometabolic conditions (diabetes, advanced liver or renal disease).</p><p><em>Efficacy against RSV-associated LRTD</em> <em>during the first RSV season (confirmatory analysis) </em></p><p>The primary objective was to demonstrate efficacy in the prevention of a first episode of confirmed RSV-A and/or B associated LRTD during the first RSV season. Confirmed RSV cases were determined by quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) on nasopharyngeal swab. LRTD was defined based on the following criteria: the participant must have experienced at least 2 lower respiratory symptoms/signs including at least 1 lower respiratory sign for at least 24 hours, or experienced at least 3 lower respiratory symptoms for at least 24 hours. Lower respiratory symptoms included: new or increased sputum, new or increased cough, new or increased dyspnoea (shortness of breath). Lower respiratory signs included: new or increased wheezing, crackles/rhonchi, respiratory rate &ge;&nbsp;20 respirations/min, low or decreased oxygen saturation (O<sub>2</sub> saturation &lt;&nbsp;95% or &le;&nbsp;90% if baseline is &lt;&nbsp;95%) or need for oxygen supplementation.</p><p>&nbsp;</p><p>Vaccine efficacy overall and by subgroups is presented in Table 2.</p><p>Efficacy in preventing first RSV-associated LRTD with an onset from 15&nbsp;days after vaccination compared to placebo was 82.6% (96.95% confidence interval of 57.9% to 94.1%) in participants 60&nbsp;years of age and older. Vaccine efficacy against RSV-LRTD was observed through the median follow-up period of 6.7&nbsp;months. Vaccine efficacy against RSV A-associated LRTD cases and RSV B-associated LRTD cases was 84.6% (95% CI [32.1, 98.3]) and 80.9% (95% CI [49.4, 94.3]), respectively.</p><p><u>&nbsp;</u></p><p><strong>Table&nbsp;2. Efficacy analysis</strong> <strong>during the first RSV season (confirmatory analysis): First RSV-associated LRTD overall, by age and co-morbidity subgroups (modified exposed set)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td rowspan="2" style="vertical-align:bottom"><p><strong>Subgroup</strong></p><p>&nbsp;</p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Arexvy</strong></p></td><td colspan="3" style="vertical-align:bottom"><p><strong>Placebo</strong></p></td><td rowspan="2" style="vertical-align:bottom"><p><strong>%&nbsp;Efficacy </strong></p><p><strong>(CI)<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:bottom"><p><strong>n</strong></p></td><td style="vertical-align:bottom"><p><strong>Incidence rate per 1&nbsp;000 person-years</strong></p></td><td style="vertical-align:bottom"><p><strong>N</strong></p></td><td style="vertical-align:bottom"><p><strong>n</strong></p></td><td style="vertical-align:bottom"><p><strong>Incidence rate per 1&nbsp;000 person-years</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall<br />(&ge;&nbsp;60&nbsp;years)<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>12&nbsp;466</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>12&nbsp;494</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>5.8</p></td><td style="vertical-align:top"><p>82.6 (57.9, 94.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>60-69&nbsp;years</strong></p></td><td style="vertical-align:top"><p>6&nbsp;963</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>6&nbsp;979</p></td><td style="vertical-align:top"><p>21</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>81.0 (43.6, 95.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>70-79&nbsp;years</strong></p></td><td style="vertical-align:top"><p>4&nbsp;487</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>4&nbsp;487</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>6.5</p></td><td style="vertical-align:top"><p>93.8 (60.2, 99.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Participants with at least 1 comorbidity<u> </u>of interest &nbsp;</strong></p></td><td style="vertical-align:top"><p>4&nbsp;937&nbsp;</p></td><td style="vertical-align:top"><p>1&nbsp;</p></td><td style="vertical-align:top"><p>0.4&nbsp;</p></td><td style="vertical-align:top"><p>4&nbsp;861&nbsp;</p></td><td style="vertical-align:top"><p>18&nbsp;</p></td><td style="vertical-align:top"><p>6.6&nbsp;</p></td><td style="vertical-align:top"><p>94.6 (65.9, 99.9)&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>CI&nbsp;=&nbsp;Confidence Interval (96.95% for the overall (&ge;&nbsp;60&nbsp;years) and 95% for all subgroup analyses). Two-sided exact CI for vaccine efficacy is derived based on Poisson model adjusted by age categories and regions.</p><p><sup>b</sup>Confirmatory objective with pre-specified success criterion of lower limit of the 2-sided CI for vaccine efficacy above 20%</p><p>N&nbsp;=&nbsp;Number of participants included in each group</p><p>n&nbsp;=&nbsp;Number of participants having first occurrence of RSV-confirmed LRTD occurring from Day 15 post vaccination</p><p><u>&nbsp;</u></p><p>Vaccine efficacy in the subgroup of participants 80&nbsp;years of age and older (1&nbsp;016 participants in Arexvy vs 1&nbsp;028 participants in placebo) cannot be concluded due to the low number of total cases accrued (5 cases).</p><p>&nbsp;</p><p>Amongst 18 RSV-LRTD cases with at least 2 lower respiratory signs or preventing everyday activities, 4 cases of severe RSV-LRTD requiring oxygen supplementation occurred in the placebo group compared to, none in the Arexvy group.</p><p>Efficacy against RSV-associated LRTD over 2 RSV seasons</p><p>Over 2 RSV seasons (up to end of second season in Northern Hemisphere), with a median follow-up time of 17.8 months, vaccine efficacy against RSV-associated LRTD was 67.2% (97.5% CI [48.2, 80.0]) in participants 60 years of age and older (30 cases in the Arexvy group and 139 cases in the placebo group).</p><p>Vaccine efficacy against RSV-associated LRTD was similar in the subgroup of participants with at least one comorbidity of interest.</p><p>A second dose of vaccine administered 12 months after the first dose did not confer additional efficacy benefit.</p><p>Immunogenicity in adults 50 through 59 years of age at increased risk for RSV disease</p><p>The non-inferiority of the immune response to Arexvy in adults 50 through 59 years of age compared to adults 60 years of age and older, where vaccine efficacy against RSV-associated LRTD was demonstrated, was evaluated in a Phase III, observer-blind, randomised, placebo-controlled study.</p><p>Cohort 1 consisted of participants 50 through 59 years of age separated in 2 sub-cohorts (Adults-AIR and Adults-non-AIR) according to their medical history. Adults-AIR (adults at increased risk) sub-cohort consisted of participants with pre-defined, stable, chronic medical conditions leading to an increased risk for RSV disease (Arexvy, N= 386; placebo, N= 191) such as chronic pulmonary disease, chronic cardiovascular disease, diabetes, chronic kidney or liver disease. Adults-non-AIR sub-cohort consisted of participants without pre-defined, stable, chronic medical conditions (Arexvy, N= 383; placebo, N= 192). Cohort 2 (OA; older adults) consisted of participants 60 years of age and older (Arexvy, N= 381).</p><p>The primary immunogenicity objectives were to demonstrate non inferiority of the humoral immune response (in terms of RSV-A and RSV-B neutralising titers) following the administration of Arexvy at 1-month post-vaccination in participants 50 through 59 years of age with and without pre-defined, stable, chronic medical conditions leading to an increased risk for RSV disease, compared to participants 60 years of age and older.</p><p>Table&nbsp;3. Summary of adjusted GMT and SRR values, and adjusted GMT ratios and SRR differences in terms of RSV-A and RSV-B neutralising titers (ED60) in adults 60&nbsp;years of age and older (OA) relative to adults 50 through 59&nbsp;years of age with (Adults-AIR) and without (Adults-non-AIR) pre-defined, stable, chronic medical conditions<sup>a</sup> leading to an increased risk for RSV disease &ndash; Per Protocol Set</p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>RSV-A neutralising titers (ED60)</strong></p></td></tr><tr><td><p><strong>&nbsp;</strong></p></td><td><p><strong>Adjusted GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Adjusted GMT ratio</strong></p><p><strong>(95% CI)<sup> b</sup></strong></p></td><td><p><strong>SRR (%)</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>SRR difference </strong><strong>(95% CI)<sup> </sup><sup>c</sup></strong></p></td></tr><tr><td><p><strong>OA</strong></p></td><td><p>7 440.1</p><p>(6 768.4, 8 178.5)</p></td><td rowspan="2"><p>0.8</p><p>(0.7, 1.0)</p></td><td><p>80.4</p><p>(75.8, 84.5)</p></td><td rowspan="2"><p>-6.5</p><p>(-12.1, -0.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adults-AIR</strong></p></td><td style="vertical-align:top"><p>8 922.7</p><p>(8 118.2, 9 806.9)</p></td><td style="vertical-align:top"><p>86.9</p><p>(82.8, 90.3)</p></td></tr><tr><td><p><strong>OA</strong></p></td><td style="vertical-align:top"><p>7 492.6</p><p>(6 819.1, 8 232.7)</p></td><td rowspan="2"><p>1.0</p><p>(0.8, 1.1)</p></td><td><p>80.4</p><p>(75.8, 84.5)</p></td><td rowspan="2"><p>-2.4</p><p>(-8.3, 3.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adults-non-AIR </strong></p></td><td style="vertical-align:top"><p>7 893.5</p><p>(7 167.5, 8 692.9)</p></td><td style="vertical-align:top"><p>82.8</p><p>(78.3, 86.8)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>RSV-B neutralising titers (ED60)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td><p><strong>Adjusted GMT</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>Adjusted GMT ratio<sup>b</sup></strong></p></td><td><p><strong>SRR</strong></p><p><strong>(95% CI)</strong></p></td><td><p><strong>SRR difference <sup>c</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>OA</strong></p></td><td><p>8 062.8</p><p>(7 395.9, 8 789.9)</p></td><td rowspan="2"><p>0.8</p><p>(95% CI</p><p>[0.7, 0.9])</p></td><td><p>74.5</p><p>(69.5, 79.0)</p></td><td rowspan="2"><p>-7.2</p><p>(95% CI</p><p>[-13.3, -0.9])</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adults-AIR</strong></p></td><td><p>10 054.7</p><p>(9 225.4, 10 958.7)</p></td><td><p>81.6</p><p>(77.1, 85.6)</p></td></tr><tr><td><p><strong>OA</strong></p></td><td><p>8 058.2</p><p>(7 373.1, 8 807.0)</p></td><td rowspan="2"><p>0.9</p><p>(97.5% CI</p><p>[0.8, 1.0])</p></td><td><p>74.5</p><p>(69.5, 79.0)</p></td><td rowspan="2"><p>-3.7</p><p>(97.5% CI</p><p>[-11.1, 3.7])</p></td></tr><tr><td style="vertical-align:top"><p><strong>Adults-non-AIR</strong></p></td><td><p>9 009.5</p><p>(8 226.8, 9 866.6)</p></td><td><p>78.2</p><p>(73.3, 82.6)</p></td></tr></tbody></table><p><sup>a </sup>Pre-defined, stable, chronic medical conditions such as chronic pulmonary disease, chronic cardiovascular disease, diabetes, chronic kidney or liver disease.</p><p><sup>b,c </sup>The prespecified criteria for non-inferiority of the immune responses were defined as the 2-sided 95% or 97.5% CI upper limits (UL) on the adjusted GMT ratios (OA over Adults-AIR or Adults-non-AIR) &le; 1.5 and the UL of the 2-sided 95% or 97.5% CI on the SRR difference (OA minus Adults-AIR or Adults-non-AIR) &le; 10% in participants 60&nbsp;years of age and older (OA) relative to participants 50 through 59&nbsp;years of age with (Adults-AIR)&nbsp; or without (Adults-non-AIR) pre-defined, stable, chronic medical conditions leading to an increased risk for RSV disease</p><p>ED60: Estimated dilution 60; CI = Confidence interval; GMT = Geometric mean titer; SRR = Seroresponse rate</p><p>The non-inferiority criteria of the immune responses for the RSV-A and RSV-B neutralising titers were met. The efficacy of Arexvy, in adults 50 through 59&nbsp;years of age at increased risk for RSV disease, can be inferred following comparison of the immune response in adults 50 through 59&nbsp;years of age with the immune response in adults 60&nbsp;years of age and older in whom vaccine efficacy was demonstrated.</p><p><u>&nbsp;</u></p><p><u>Paediatric population </u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with</p><p>Arexvy in one or more subsets of the paediatric population in prevention of lower respiratory tract disease caused by respiratory syncytial virus (see section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity.</p><p>Reproductive and developmental studies in rabbits with Arexvy or with an unadjuvanted RSVPreF3 vaccine did not reveal vaccine-related effects on female fertility, pregnancy, or embryo-foetal or offspring development</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1&nbsp;&nbsp;&nbsp;&nbsp; List of excipients<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-weight:normal'><span style='mso-element:
field-begin'></span></span><span style='mso-bidi-font-size:11.0pt'> DOCVARIABLE
vault_nd_989081a8-58e3-4f93-a1d2-7f3c4bb2be8e \* MERGEFORMAT </span><span
style='mso-bidi-font-size:11.0pt;font-weight:normal'><span style='mso-element:
field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-weight:normal'><span style='mso-element:
field-end'></span></span><![endif]--></p><p><em>&nbsp;</em></p><p><u>Powder (RSVPreF3 antigen) with Quantity</u></p><p>Trehalose dihydrate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.7 mg</p><p>Polysorbate 80 (E 433)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.18 mg</p><p>Potassium dihydrogen phosphate (E 340)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.29 mg</p><p>Dipotassium phosphate (E 340)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0.26 mg</p><p>&nbsp;</p><p><u>Suspension (AS01E Adjuvant System) with Quantity</u></p><p>3-O-desacyl-4&rsquo;-monophosphoryl lipid A (MPL)&nbsp;&nbsp;&nbsp;&nbsp; 25 &micro;g</p><p>Purified Quillaja Saponin (QS-21) <sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;25 &micro;g</p><p>Dioleoyl phosphatidylcholine (E 322)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;500 &micro;g</p><p>Cholesterol&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;125 &micro;g</p><p>Sodium chloride&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4 mg</p><p>Disodium phosphate, anhydrous (E 339)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.15 mg</p><p>Potassium dihydrogen phosphate (E 340)&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.54 mg</p><p>Water for injections&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<em>q.s. ad</em> 0.5 mL</p><p>&nbsp;</p><p>For adjuvant see also section 2</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years

After reconstitution
Chemical and physical in-use stability has been demonstrated for 4 hours at 2 °C – 8 °C or at room temperature up to 25 °C.
From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 4 hours.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Arexvy is presented as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Powder for 1 dose in a vial (type I glass) with a stopper (butyl rubber) and a mustard green flip-off cap (antigen).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Suspension for 1 dose in a vial (type I glass) with a stopper (butyl rubber) and a brown flip-off cap (adjuvant).</p><p>&nbsp;</p><p>Arexvy is available in a pack size of 1 vial of powder plus 1 vial of suspension or in a pack size of 10 vials of powder plus 10 vials of suspension.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The powder and the suspension must be reconstituted prior to administration.</p><p><img alt="" width="285" height="200" src="data:image/png;base64,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" /></p><p><u>How to prepare Arexvy</u></p><p>Arexvy must be reconstituted prior to administration.</p><p>&nbsp;</p><p>1. Withdraw the entire contents of the vial containing the suspension into a syringe.</p><p>2. Add the entire contents of the syringe into the vial containing the powder.</p><p>3. Gently swirl until the powder is completely dissolved.</p><p>&nbsp;</p><p>The reconstituted vaccine is an opalescent, colourless to pale brownish liquid.</p><p>&nbsp;</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation of appearance. If either is observed, do not administer the vaccine.</p><p>&nbsp;</p><p>Chemical and physical in-use stability has been demonstrated for 4 hours at 2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C or at room temperature up to 25&nbsp;&deg;C.</p><p>From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 4 hours.</p><p>&nbsp;</p><p><u>Before administration</u></p><p>1. Withdraw 0.5 mL of the reconstituted vaccine into the syringe.</p><p>2. Change the needle so that you are using a new needle.</p><p>&nbsp;</p><p>Administer the vaccine intramuscularly.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p><p>AREXVY is a trademark owned by or licensed to the GSK group of companies.</p><p>&copy;2024 GSK group of companies or its licensor.</p><p>&nbsp;</p><p>&nbsp;</p><p>MARKETING AUTHORISATION HOLDER<!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_c913cb8c-0490-4381-a5b8-73cf65818e89 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; KSA.</p><p>*Member of GSK group of companies</p><p>&nbsp;</p><p><strong>Manufactured by :</strong></p><p>GlaxoSmithKline Biologicals SA, Avenue Fleming, 20, 1300 Wavre, Belgium</p><p><strong>Release by:</strong></p><p>GlaxoSmithKline Biologicals SA* Rue de l&rsquo;Institut 89 , 1330 Rixensart Belgium</p><p>&nbsp;</p><p><strong>DATE OF REVISION OF THE TEXT</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-GB style='mso-bidi-font-size:
11.0pt'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_161c69d0-bc4e-4529-82ca-bd19e3ba7aad \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><span
lang=EN-GB style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span><![endif]--><strong>&nbsp;: </strong>26 August 2024</p><p>&nbsp;</p><p><strong>VERSION NUMBER: </strong>EMAv05 (26-08-2024)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia 
Address: P.O. Box 22617 Jeddah 21416 – KSA.
*Member of GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	
DATE OF REVISION OF THE TEXT  : 26 August 2024
	
	VERSION NUMBER: EMAv05 (26-08-2024)

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>